

Dedalus
HEALTHCARE SYSTEMS GROUP

Covid-19 Vaccination Process

LIFE FLOWS THROUGH OUR SOFTWARE

The challenge

Never in human history a vaccination campaign has been carried out with the following characteristics:

- Between **60% and 70% of a country's population will need to be vaccinated** in the shortest time possible
- It will be used Vaccines whose efficacy and safety have never really been tested in the field
- **Logistics of different** types of vaccines will have to be managed with complex transport and storage problems
- Individual patients will have to be managed according to pre-assigned vaccination priorities: this **pre-assignment is going to be complex**
- The phase 4, following a phase 3 accelerated as never before in the history of the development of a vaccine, **will have to be carried out as a kind of phase 3bis**
- The relationship with the healthy citizen and with the **patient suffering from any chronic or acute disease cannot be treated in the classical way** of a vaccination campaign

Covid-19 the full vaccination process

National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress

Covid-19 the full vaccination process - details



National level
Pre-population analysis and pre-allocation in time-type clusters

Evidence of specific categories of population, Ex: Health Professionals, securities

Evidence of specific categories of population: Chronic Risks, Fragile Risk

Regional level
Scheduling of activities by cluster

Eligible patients planning and start of the individual pathway

Define the needs in term of doses to be acquired and distributed

Patient Invitation, follow up on no shows, re-booking Multichannel

Regional level
Vaccination Management of and monitoring criteria assignment

1° and 2°,3° dose administration
Patient Check-In
Vaccine Administration
Drug-Vaccine Surveillance
Questionary & Monitoring
Manage reminders

Regional level
Clinical monitoring of tests, vital signs, physical state

Patient follow-up reporting information

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

Patient empowerment, recalls, re-testing

National / Regional level
Business intelligence. Monitoring of side effects, status/progress

Monitor the Vaccination campaign progresses and clinical response

SUPPLY CHAIN PROCESS

Dedalus
HEALTHCARE SYSTEMS GROUP

Patients enrollment and plan of care

Our application – example slides

LIFE FLOWS THROUGH OUR SOFTWARE

Co4C: Eligible Population incoming



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



506417
TARGET POPULATION
88 % delle pratiche

7
ADVERSE EVENTS
0 % delle pratiche

52347
ADMINISTERED VACCINATIONS (1st Dose)
9 % delle pratiche

0
ADMINISTERED VACCINATIONS (2nd Dose)
0 % delle pratiche

8
ENROLLED CITIZENS
0 % delle pratiche

17091
CITIZENS WITH REPORTED FOLLOW UP
3 % delle pratiche

The **Control Center** has a powerful Dashboard, that allows to view **the target list received after the population analysis process**, is shown.

©CO4C - Covid-19 Vaccination Process Support

Version 2.1.0-SNAPSHOT

Co4C: Vaccination Point select patients of Cluster and define treatment protocol



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



Criteria

Pathologies: Diabetes
Age Cohort: 60-70
Notified By: GP
Area: Milan Cohort South East
Care giver: Dr. Steve Chen
Profession: Pharmacist

Protocol

Protocol: AZD1222: AstraZeneca – Half dose

BNT162b2: Pfizer e BioNTech
AZD1222: AstraZeneca – Half dose
AZD1222: AstraZeneca – Full dose
Cancel
✔ Confirm

Select patients and citiziens using **criteria** based on demographic data, profession
pathology and defines a treatment protocol

Co4C: Treatment Protocol



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



Ccm
Michael Taylor
Individual Vaccination Plan
Reported Information
Search...
10
Tot: 7
1
+ Add service
Notes
Edit
Send to Planner

Patient: TESTBAR TESTBAR (AGE: 40.5)

Internal Case: ID: 1384 DATA: 12/1/2020

Created by: OPERATOR

Applied Protocol: AstraZeneca Full Dose Protocol - Diabetic patient

Treatment Protocol

Code	Description	Suggested Timing	Assigned Timing	Status
DIA1	FULL DOSE (1st)	T0	T0	●
DIA2	FEEDBACK REPORT	T0 + 24H	T0 + 24H	●
DIA3	BLOOD GLUCOSE MONITORING	T0 + 24h	T0 + 24h	●
DIA4	DIABETOLOGICAL VIRTUAL VISIT	T0 + 24h	T0 + 24h	●
DIA5	FULL DOSE (2nd) - T1	T0 + 14days	T0 + 14days	●
DIA6	FEEDBACK REPORT	T1 + 24h	T1 + 48h	●
DIA7	BLOOD GLUCOSE MONITORING	T1 + 24h	T1 + 24h	●

Planning: book vaccinations



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



Patient Enrollment System
Patient-provider association

7 Patients Sort By: Name

Patient	Conditions	Age	Date of birth	Area	Profession
Daniele Siciliano	Diabete	48 years old	24/11/1972	Milan cohort south east	Pharmacist
James Ford	Diabete	51 years old	26/05/1967	Milan cohort south east	Pharmacist
Roberta Lupoli	Diabete	33 years old	26/05/1985	Milan cohort south east	Pharmacist
Thomas Brody	Diabete	38 years old	26/05/1979	Milan cohort south east	Pharmacist
Brandon Lee	Diabete	34 years old	26/05/1984	Milan cohort south east	Pharmacist
Carl Potter	Diabete	59 years old	26/05/1963	Milan cohort south east	Pharmacist
Rita Fusilli	Diabete	58 years old	04/10/1964	Milan cohort south east	Pharmacist

4 Providers

Provider	Area	Vaccine	Available daily doses	Available total doses
PROVIDER 1	Milan cohort south east	AZD1222:AstraZeneca – Half dose	24/24	129/512
PROVIDER 2	Milan cohort south east	AZD1222:AstraZeneca – Half dose	5/32	29/312
PROVIDER 3	Milan cohort south east	AZD1222:AstraZeneca – Half dose	8/24	329/512
PROVIDER 4	Milan cohort south east	AZD1222:AstraZeneca – Half dose	24/24	129/512

Co4C: Cluster 1: patients enrolled



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



506417 TARGET POPULATION 88 % delle pratiche	7 ADVERSE EVENTS 0 % delle pratiche	52347 ADMINISTERED VACCINATIONS (1st Dose) 9 % delle pratiche
0 ADMINISTERED VACCINATIONS (2nd Dose) 0 % delle pratiche	8 ENROLLED CITIZENS 0 % delle pratiche	17091 CITIZENS WITH REPORTED FOLLOW UP 3 % delle pratiche

©CO4C - Covid-19 Vaccination Process Support

Version 2.1.0-SNAPSHOT

A4P Multichannel Platform
Invitation Receiving



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress

Welcome Marco F

Message

12 17 2020 - 11:
Your local health organization stru
You are invited t
Covid19 vaccinat
campaign. Please
up on Jan 10th a
at local vax locat
Please confirm yo
presence insertin
Covid self-evalua
case you don't w
join vaccination
campaign, please
NO

13 17 2020 - 09:
Contact supplier
ha f-yearly O2
replacements.

13 17 2020 11:4
Check the seal o
mask on the nex

Informed consent f

Institution:	Southern Cross Fertility Centre
Title of the Study	Influence of Luteinizing Hormone (LH) o (LH/M2-Oocyte) (ClinicalTrials.gov Identifie
Study director	M R Bharucha, PhD (Sat Kaival Pvt. Ltd, An
Principal investigators in different locations	1. Nayana Patel, MD (Sat Kaival Hospital Pvt. Ltd, 2. Faram Irani, MD (Southern Cross Fertility Cente 3. Asha Baxi, MD, FRCOG (Disha Fertility & Surgic dia)
Sponsor:	Southern Cross Fertility Centre in collaboration w Surgical Centre, Indore, India
Locations:	Sat Kaival Hospital Pvt. Ltd, Anand, Gujarat Southern Cross Fertility Center, Mumbai, India Disha Fertility & Surgical Hospital, Indore, India

Participant's Printed Name: ____________

COVID

Epidemiological valutation

Stay in a country with high covid risk *
○ Yes
○ No
Declare if you have been in a country/locality with high covid risk
*mandatory field

Exposition to certain covid cases (alive or dec
○ Yes
○ No
*mandatory field

Exposition to suspected cases*
○ Yes
○ No
*mandatory field

Epidemiologic
valutation

Connections with people coming back f
high risk country/locality*
○ Yes
○ No
*mandatory field

Connections with relatives of suspecte
○ Yes
○ No
*mandatory field

Number of cohabitants
Insert number of cohabitants
*mandatory field

☐ According to the article 46 and 47 D.P.R. n 45/2000, conscious that f declarations are punished accordi penal code and the specific laws i field, as claimed by the disposition 76 of D.P.R. n. 445/2000, I declare the entered information are true.
*mandatory field

The information have been correctly sent

A4P Multichannel Platform
SMS received for invitation

National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



Your local health organizat
ASL. You are invited to join
vaccination campaign. Plea
on Jan 10th at 09:00 at loc
location. Please confirm yo
downloading A4P at follow
www.abc.com and insert y
self-evaluation. In case you
to join vaccination campaig

A
TYPE MESSAGE
A4P
APP4PATIENT
Percorsi Terapeutici
Messa
Come Fare Per
Questio
e Tes
COVID
Self-declaration COVID
Registration sectio
How to prevent the infection
Useful numbers

Epidemiological valutation

Stay in a country with high covid risk ?*
Yes
No
Declare if you have been in a country/locality with high covid risl
*mandatory field

Exposition to certain covid cases (alive or de
Yes
No
*mandatory field

Exposition to suspected cases*
Yes
No
*mandatory field

Epidemiological valutation

Connections with people coming back from high risk country/locality*
Yes
No
*mandatory field

Connections with relatives of suspected cases*
Yes
No
*mandatory field

Number of cohabitants
Insert number of cohabitants
*mandatory field

☐ According to the article 46 and 47 of the D.P.R. n 45/2000, conscious that false declarations are punished according to the penal code and the specific laws in the field, as claimed by the disposition of art 76 of D.P.R. n. 445/2000, I declare that the entered information are true.
*mandatory field

The information have been correctly sent

A4P Multichannel Platform
Localizing Administration Hub



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress


Giardino Farpi Vignoli
Opificio Golinelli
Caffè Atlantico
Ospedale Maggiore Carlo Alberto Pizzardi
Esselunga di Santa Viola
Eurospin
Lidl
Cinema Teatro Orione
Grand Hotel Elite
Viale M. K. Gandhi
Via Tolmino
Cimitero Monumentale della Certosa
Parco Nicholas Green
QUARTIERE SARAGOZZA
Stadio Renato Dall'Ara
Piscina Carmen Longo Stadio 25m
BARCA
Arco Del Meloncello
Teatro Celebrazioni
Villa Spada
08
13
15
21

Administration Hub
(Doctor Smith)

Km 3,4

Via dei Capuleti, 28 - 00164 Roma

Currently crowded

Co4C: Check in for the first Dose



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



506417
TARGET POPULATION
88 % delle pratiche

7
ADVERSE EVENTS
0 % delle pratiche

52347
ADMINISTERED VACCINATIONS (1st Dose)
9 % delle pratiche

0
ADMINISTERED VACCINATIONS (2nd Dose)
0 % delle pratiche

8
ENROLLED CITIZENS
0 % delle pratiche

17091
CITIZENS WITH REPORTED FOLLOW UP
3 % delle pratiche

©CO4C - Covid-19 Vaccination Process Support

Version 2.1.0-SNAPSHOT

Co4C Worklist



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress

Every Vaccination Point has its own agenda, that can be filtered by Month, Week, Day

The list displays information about Demographics, Vaccination, Contacts.

After having prepared the dose will be used for every patient, the operator can check the correct pairing patient-dose



November 30, 2020

Monday

- JOHN DOE - Male, Age 71 || mobile Phone 333 2345678 || First Dose AZD1222: AstraZeneca || Test Boulevard, 75000 Paris
- SUSAN MARPLE - Female, Age 65|| mobile Phone 555 2345678 || First Dose AZD1222: AstraZeneca || Demo Square, 75000 Paris

November 30, 2020

Monday

JOHN DOE
Male
Age 71
Mobile Phone 333 2345678 First Dose AZD1222: AstraZeneca
Test Boulevard, 75000 Paris

SUSAN MARPLE
Female
Age 65
Mobile Phone 555 2345678 First Dose AZD1222: AstraZeneca
Demo Square, 75000 Paris

Via A4H: dose scanning and administration

- **National level** Pre-population analysis and pre-allocation in time-type clusters
- **Regional level** Scheduling of activities by cluster
- **Regional level** Vaccination Management of and monitoring criteria assignment
- **Regional level** Clinical monitoring of tests, vital signs, physical state
- **National/regional level** Execution of recall and / or interruption for single patient or sub cluster
- **National / Regional level** Business intelligence. Monitoring of side effects, status/progress



Let's start!

Scan the patient's document or health card or type in his basic information.

The vaccine scanned corresponds to as prescribed and it is is ready for administration

Name
Surname
Date of birth
Document Number
NEXT
Scan the ID document
Front scan
Back scan
Type of Vaccine
SCAN VACCINE
Vaccine scan
Vaccine scan

C4H: Stock administration

- **National level** Pre-population analysis and pre-allocation in time-type clusters
- **Regional level** Scheduling of activities by cluster
- **Regional level** Vaccination Management of and monitoring criteria assignment
- **Regional level** Clinical monitoring of tests, vital signs, physical state
- **National/regional level** Execution of recall and / or interruption for single patient or sub cluster
- **National / Regional level** Business intelligence. Monitoring of side effects, status/progress



COVID 19 Vaccine BNT162b1

Stock	24 Doses
LOT	12644759301
Expiry Date	14/01/2028
Supplier	Pfzier Limited
Maintenance	Preserve in fridge at -80 -60 degree

COVID 19 Vaccine BNT162b1

Stock	23 Doses
LOT	12644759301
Expiry Date	14/01/2028
Supplier	Pfzier Limited
Maintenance	Preserve in fridge at -80 -60 degrees

No grade 1 or greater change in routine clinical laboratory values or laboratory abnormalities were observed for most participants after either of the BNT162b1 vaccinations.
Of those with laboratory changes, the largest changes were decreases in the lymphocyte count after the first dose in 8.3% (1 out of 12), 45.5% (5 out of 11) and 50.0% (6 out of 12) of participants who received 10 µg, 30 µg and 100 µg BNT162b1, respectively. One participant each in the 10-µg (8.3% (1 out of 12)) and 30-µg (9.1% (1 out of 11)) groups and 4 participants in the 100-µg group (33.3% (4 out of 12)) had grade 3 decreases in the lymphocyte count. These decreases in lymphocyte count after the first dose were transient and returned to normal 6–8 days after vaccination.

In addition, grade-2 neutropenia was noted 6–8 days after the second dose in 1 participant each in the 10-µg and 30-µg BNT162b1 groups. These two participants continue to be followed in the study, and no adverse events or clinical manifestations of neutropenia have been reported to date. None of the post-vaccination abnormalities observed were associated with clinical findings.

Read More

Co4C: Follow up



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



506417
TARGET POPULATION
88 % delle pratiche

7
ADVERSE EVENTS
0 % delle pratiche

52347
ADMINISTERED VACCINATIONS (1st Dose)
9 % delle pratiche

0
ADMINISTERED VACCINATIONS (2nd Dose)
0 % delle pratiche

8
ENROLLED CITIZENS
0 % delle pratiche

17091
CITIZENS WITH REPORTED FOLLOW UP
3 % delle pratiche

©CO4C - Covid-19 Vaccination Process Support

Version 2.1.0-SNA HOT

A4P: Patients send a follow up



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress

Home Ca
Mario I
Anna B
Welcome Mario Rossi
Therapy
Therapy Plan
Care Plan
Welcome Mario Rossi
Calendar Care Plane
DECEMBER
Mon Tue Wed Thu Fri Sat Sun
31 1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31 1 2 3
Feedback report
Virtual visit
Vaccination
Vaccine recall
Follow up criteria
Questionnaires
Test
Have you any morbidity?
Standard
Diabetes
Hypertension
Diabetes / Hypertension
Never
1 2 3 4 5 6 7 8 9 10 ...
Welcome Mario Rossi
Feedback report
Feeling lightheaded or faint
Breathing difficulties – such as fast, shallow breathing
Wheezing
A fast heartbeat
Clammy skin
SEND
The information have been correctly sent
CLOSE

Co4C: Doctor reporting: self-evaluation patient answers


National level
Pre-population analysis and pre-allocation in time-type clusters
Regional level
Scheduling of activities by cluster
Regional level
Vaccination
Management of and monitoring criteria assignment
Regional level
Clinical monitoring of tests, vital signs, physical state
National/regional level
Execution of recall and / or interruption for single patient or sub cluster
National / Regional level
Business intelligence.
Monitoring of side effects, status/progress



Patient Data

Id Patient	Name	Birth Date	Telephone Contact	Email	Zip Code
1524552	Prova Prova		35541256	5.1.2e@prova.it	95030

Seriousness

- ☐ Death
- ☐ Life-threatening
- ☐ Hospitalization (initial or prolonged)
- ☐ Disability - significant, persistent, or permanent change
- ☐ Requires intervention to prevent permanent impairment or damage

Treatment

- ☐ Use an adrenaline auto-injector if the person has one
- ☐ Call 999 for an ambulance immediately (even if they start to feel better)
- ☐ Lie the person down flat
- ☐ Give another injection after 5 to 15 minutes

Symptoms

- ☑ Feeling lightheaded or faint
- ☐ Breathing difficulties – such as fast, shallow breathing
- ☑ Wheezing
- ☐ A fast heartbeat
- ☐ Clammy skin
- ☐ Confusion and anxiety
- ☐ ollapsing or losing consciousness

Reporting

Destination:

Detail:

… through patient self-evaluation

Co4C: Doctor reporting can register adverse reactions


National level Pre-population analysis and pre-allocation in time-type clusters

Regional level Scheduling of activities by cluster

Regional level Vaccination Management of and monitoring criteria assignment

Regional level Clinical monitoring of tests, vital signs, physical state

National/regional level Execution of recall and / or interruption for single patient or sub cluster

National / Regional level Business intelligence. Monitoring of side effects, status/progress

☑


Patient Data

Id Patient	Name	Birth Date	Telephone Contact	Email	Zip Code
1524552	Prova Prova		35541256	prova@prova.it	95030

Seriousness

- ☐ Death
- ☐ Life-threatening
- ☐ Hospitalization (initial or prolonged)
- ☐ Disability - significant, persistent, or permanent change
- ☐ Requires intervention to prevent permanent impairment or damage

Treatment

- ☐ Use an adrenaline auto-injector if the person has one
- ☐ Call 999 for an ambulance immediately (even if they start to feel better)
- ☐ Lie the person down flat
- ☐ Give another injection after 5 to 15 minutes

Symptoms

- ☑ Feeling lightheaded or faint
- ☐ Breathing difficulties – such as fast, shallow breathing
- ☑ Wheezing
- ☐ A fast heartbeat
- ☐ Clammy skin
- ☐ Confusion and anxiety
- ☐ ollapsing or losing consciousness

Reporting

Destination:

Detail:

for example after tele-visit

Co4C: Monitoring patient conditions



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination
Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence.
Monitoring of side effects, status/progress


patient-synoptic
Non sicuro
172.19.23.219/patient-synoptic/#/634441/control/synoptic
PATIENT
SYNOPTIC
Assigning Authorities
female
Allergies
Procedures
Save
Reset
Delete
Export CSV
Export IMAGE
Hide
Systolic pressure (mmhg)
Hide
Diastolic pressure (mmhg)
140
130
120
110
100
90
80
Value
Mar 10 12AM
Mar 10 3AM
Mar 10 6AM
Mar 10 9AM
Mar 10 12PM
Mar 10 3PM
Mar 10 6PM
Date
Enable Zoom
More content avai
Temperature

ANGELA MARIELLA Identifier: **BLBMLL63M53E290B** Born on: **1963-08-13** **57 years**

Select configuration: Clinical view

Questionnaire

Date	Title	View
2020-03-20	Self Assessment Questionnaire	pdf
2020-03-20	FollowUp Questionnaire	pdf
2020-03-09	Rare Desease Questionnaire	pdf

ECG

Datetime	Heart rate	QTC	QRS	QT	View
2020-03-09 04:15:42 pm	86 bpm	419 bpm	74 bpm	350 bpm	ECG
2020-03-09 04:02:39 pm	81 bpm	414 bpm	60 bpm	357 bpm	ECG
2020-03-09 02:06:51 pm	68 bpm	399 bpm	71 bpm	375 bpm	ECG
2020-03-09 01:41:25 pm	75 bpm *	404 bpm *	69 bpm *	362 bpm *	ECG

Blood pressure

SPO2

Datetime	Code	Value	Range	Interpretation
2020-03-10 12:18:12 pm	Saturazione dell'ossigeno (%)	98 %		
2020-03-10 12:18:12 pm	Indice di perfusione (PI)	2.2 P		
2020-03-10 12:18:12 pm	Frequenza cardiaca da pulsossimetro (bpm)	82 bpm		
2020-03-10 06:18:12 pm	Saturazione dell'ossigeno (%)	99 %		
2020-03-10 06:13:12 pm	Indice di perfusione (PI)	1.8 P		



Self Assessment Questionnaire

COVID-19 MONITORING SYSTEM
RESPIRATORY DISEASES EVALUATION QUESTIONNAIRE

GENERAL INFORMATION

Date: 2020-03-20 **Time:** 12:40

COMPILED BY (WHEN NOT COMPILED BY THE PATIENT)

Family name: DOE **First name:** JOHN
Acting as: CHILD
Phone: +391234567890 **Email:** john.doe@domain.com

PATIENT INFORMATION

Family name: ANGELA **First name:** MARIELLA
Tax code: BLBMLL63M53E290B **Gender:** FEMMINA
Birth date: 1963-08-13 **Birth place:** IMPERIA
Living address: - **Home address:** -
City: - **Country:** - **City:** - **Country:** -
Mobile: - **Phone:** -
Email: **Cohabitants:** 4

PATIENT EPIDEMIOLOGICAL PROFILE

RECENT STAY IN A RISK COUNTRY/AREA: ☒Yes ☐ No ☐ Not known
IF SO, SPECIFY COUNTRY: -
RISK LOCATION DEPARTURE DATE: 2020-03-09
EXPOSURE TO CONFIRMED CASES (living or deceased): ☐Yes ☒ No
EXPOSURE TO SUSPECTED CASES (high probability cases): ☒Yes ☐ No
CONTACTS WITH PEOPLE RETURNED FROM RISK CONTRIES/AREAS: ☒Yes ☐ No
CONTACT WITH RELATIVES OF SUSPECTED CASES: ☐Yes ☒ No

Dedalus

#TOGETHER4SUCCESS

Dedalus
HEALTHCARE SYSTEMS GROUP

Focus on: KPI to governance and campaign monitoring

LIFE FLOWS THROUGH OUR SOFTWARE

BI4H: Issues reported monitoring



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



Dedalus BI4H
Hello, Giulia
GS
Home > Overview > Issues Reported > Questionnaires
Edit
Filters
Issues tracking
Fever after 2 days (4023 • 39.11%)
Fatigue (2632 • 25.59%)
Headache (1536 • 14.93%)
Nausea (1241 • 12.06%)
Stomach ache (854 • 8.30%)
Fatigue
No
Vax 1
Vax 3
0%
100%
Fever after 2 days
Yes
No
Vax 1
Vax 2
Vax 3
Vax 4
0%
100%
Headache
No
Vax 1
Vax 3
0%
100%
Nausea
No
Vax 1
Vax 3
0%
100%
Stomach ache
Yes
No
Vax 1
Vax 3
0%
100%
Issue
Response

Vax	Injection date	Fiscal code	Surname	Age range	Fatigue Yes	Fatigue No	Fever after 2 days Yes	Fever after 2 days No	Headache No	Nausea No	Stomach ache No
Vax 1					2	7	69	1,488	7	7	7
Vax 2					-	-	1	12	-	-	-
	12/31/2020				-	-	-	1	-	-	-
		XXXFNC44P57XXXX			-	-	-	1	-	-	-
	12/31/2020	XXXFNC44P57XXXX	PAZIENTE 121024		-	-	-	1	-	-	-
			PAZIENTE 121024	65 - 80 anni	-	-	-	1	-	-	-
	03/06/2021				-	-	-	1	-	-	-
		XXXMRA30P08XXXX			-	-	-	1	-	-	-
	03/06/2021	XXXMRA30P08XXXX	PAZIENTE 265910		-	-	-	1	-	-	-

BI4H: Adverse reaction monitor



National level Pre-population analysis and pre-allocation in time-type clusters

Regional level Scheduling of activities by cluster

Regional level Vaccination Management of and monitoring criteria assignment

Regional level Clinical monitoring of tests, vital signs, physical state

National/regional level Execution of recall and / or interruption for single patient or sub cluster

National / Regional level Business intelligence. Monitoring of side effects, status/progress


Dedalus BI4H
Hello, Giulia
GS
Home > Overview > Issues Reported > Adverse Reaction Monitor
Edit
Adverse reactions tracking
1M
100K
10K
1K
Reportings
117K (56.85%)
65K (31.71%)
22K (10.72%)
1K (0.73%)
None
Local
Allergic
Systemic
Adverse reaction
Adverse reactions by age range
Systemic
None
Allergic
Local
0
Patient reactions list
25
50
100
Page 1 of 235466 (11773272 rows)
1
2
3
4
5
...
235466

Adverse reaction	Vaccine	Patient	Gender	Age range	Hospitalization	Caregiver injection	Date
None	Vax 1	XXXFNC34M67XXXX	F	> 80 anni	No	OPERATORE 967	05/26/2021
Allergic	Vax 3	XXXDNC33H02XXXX	M	> 80 anni	No	OPERATORE 415	06/01/2021
None	Vax 1	XXXCNR34H26XXXX	M	> 80 anni	No	OPERATORE 4087	05/25/2021
None	Vax 1	XXXGNR34H26XXXX	M	> 80 anni	No	OPERATORE 4087	05/25/2021
Allergic	Vax 3	XXXFNC61M01XXXX	M	15 - 64 anni	No	OPERATORE 4287	05/04/2021
Local	Vax 2	XXXLCU93H29XXXX	M	15 - 64 anni	No	OPERATORE 3017	05/30/2021
Allergic	Vax 3	XXXBNM34T70XXXX	F	> 80 anni	No	OPERATORE 1382	05/29/2021

BI4H: Vaccination campaign progress - invitations



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress


Dedalus BI4H
Hello, Giulia
GS
Home
Tracking Campaign
Invitation Tracking
Edit
Filters
Dispensers Monitoring
Invitation Tracking
Vaccinations Tracking
Patient type
FRAGILE
ALTRO
POLIZIA
SANITARIO
Age range
0 - 30 GIORNI
1 - 12 MESI
1 - 5 ANNI
6 - 14 ANNI
15 - 64 ANNI
Done invitations
To be invited
+
−

Invited
3,014
on
306,068

Status Cancel
1,980

Status No invitation
257,383

Status OK
3,014

Status Wait
43,691

Invitation tracking

Status

Data	Cancel	OK	Wait	Grand Total
11/01/2020	-	-	73	73
11/02/2020	-	-	87	87
11/03/2020	-	-	96	96
11/04/2020	-	-	87	87
11/05/2020	-	-	96	96
11/06/2020	-	-	108	108
11/07/2020	7	2	96	105
11/08/2020	10	2	112	124
11/09/2020	4	1	112	117
11/10/2020	2	2	111	115

BI4H: Vaccination campaign progress - vaccinations



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress



Dedalus BI4H
Hello, Giulia
GS
Home › Tracking Campaign › Vaccinations Tracking
Edit
Filters
Dispensers Monitoring
Invitation Tracking
Vaccinations Tracking
Injection tracking
25
20
15
10
5
Patients
01/01/2021
01/07/2021
01/12/2021
01/17/2021
01/22/2021
01/27/2021
02/01/2021
02/07/2021
02/13/2021
02/18/2021
02/25/2021
03/02/2021
03/07/2021
03/12/2021
03/17/2021
03/22/2021
03/27/2021
04/01/2021
04/06/2021
04/11/2021
04/16/2021
04/21/2021
04/26/2021
05/01/2021
05/06/2021
05/11/2021
05/16/2021
05/21/2021
05/26/2021
05/31/2021
06/05/2021
06/10/2021
06/15/2021
06/20/2021
06/25/2021
06/30/2021
07/05/2021
07/10/2021
07/15/2021
07/20/2021
07/25/2021
Date
Date
Hour
See patients list

Done
1,912
on accepted invitations
3,014

Injections by dispenser

Injection Date, Erogatore	Vaccinated patients	1° round	2° round	See details
01/01/2021	**52**	**52**	**0**	🔍
EROG ABC	52	52	0	🔍
01/02/2021	**52**	**0**	**52**	🔍
EROG ABC	52	0	52	🔍
01/03/2021	**156**	**52**	**104**	🔍
EROG ABC	156	52	104	🔍
01/04/2021	**104**	**104**	**0**	🔍
EROG ABC	104	104	0	🔍
01/05/2021	**104**	**52**	**52**	🔍
EROG ABC	104	52	52	🔍

10 20 40 Page 1 of 111 (2208 rows) ‹ 1 2 3 4 5 … 111 ›

BI4H: Monitor distribution and stocks of doses



National level
Pre-population analysis and pre-allocation in time-type clusters

Regional level
Scheduling of activities by cluster

Regional level
Vaccination Management of and monitoring criteria assignment

Regional level
Clinical monitoring of tests, vital signs, physical state

National/regional level
Execution of recall and / or interruption for single patient or sub cluster

National / Regional level
Business intelligence. Monitoring of side effects, status/progress


Dedalus BI4H
Hello, Giulia
GS
Home > Tracking Campaign > Dispensers Monitoring
Edit
Filters
Distribution of dispensers on the territory
Reset Zoom
1 km
Bartolo
Caldine
La Topaia
Serpiolle
Trespiano
Castello
Il Sodo
Fiesole
Maiano
Poggio Gherardo
Isolotto
Firenze
Soffiano
Ponte a Ema
Vaccines available (not booked)
Vaccine
Dispenser
Distribution of dispensers on the territory
Dispenser 24SP (32 · 10.74%)
Dispenser 11RE (27 · 9.06%)
Dispenser 21MA (32 · 10.74%)
Dispenser 20GI (30 · 10.07%)
Dispenser 29GI (35 · 11.74%)
Dispenser 27RNO (17 · 5.70%)
Dispenser 20AD (23 · 7.72%)
Dispenser 22AP (24 · 8.05%)
Dispenser 24AD (24 · 8.05%)
Dispenser 19ALE (21 · 7.05%)
Dispenser 15OS (- · 0.00%)
Dispenser 15OLO (- · 0.00%)
Dispenser 15EL (- · 0.00%)
Dispenser 17ELL (- · 0.00%)
Dispenser 23ORE (- · 0.00%)
Dispenser 12AN (- · 0.00%)
Dispenser 25AL (33 · 11.07%)
Vaccines available (not booked)
Viale Redi 12
Viale Giovanni Milton 1
Viale Alessandro Guidoni 261
Viale Spartaco Lavagnini 12
Viale Giovan Battista Morgagni 13
Viale Manfredo Fanti 18A
Piazza dell'Indipendenza 1
Piazza Pietro Leopoldo 12
Piazza Della Libertà 1R
Piazzale Donatello 12
Lungarno Cristoforo Colombo 12
Vax 1
Vax 2
Vax 3
Vax 4

Vaccines available (not booked)

Dispenser	Vax 1	Vax 2	Vax 3	Vax 4
Dispenser 27RNO	-	-	17	-
Dispenser 20AD	-	8	15	-
Dispenser 22AP	-	8	16	-
Dispenser 24AD	-	8	16	-

Vax 1: 107
Vax 2: 31
Vax 3: 78
Vax 4: 82